Pharmabiz1d
DORC’s ILM-Blue receives China NMPA approval; expanding global reach to prove high-quality and effective solutions to ophthalmic community
DORC’s ILM-Blue receives China NMPA approval; expanding global reach to prove high-quality and effective solutions to ophthalmic community: Jena, Germany Saturday, March 29, 202 ...
Pharmabiz1d
4Moving Biotech gets Health Canada approval to initiate phase 2a INFLAM MOTION clinical trial for knee osteoarthritis
Moving Biotech gets Health Canada approval to initiate phase 2a INFLAM MOTION clinical trial for knee osteoarthritis: Lille & Paris, France Saturday, March 29, 2025, 17:00 Hrs [I ...
Pharmabiz1d
Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor
Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor: Berlin, Germany Saturday, March 29, 2025, 12:00 Hrs [I ...
Pharmabiz1d
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...
Pharmabiz1d
CDSCO declares a total of 103 drug samples as NSQ in February
CDSCO declares a total of 103 drug samples as NSQ in February: Our Bureau, New Delhi Saturday, March 29, 2025, 13:30 Hrs [IST] The Central Drugs Standard Control Organisation (CDS ...
Pharmabiz1d
Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial
Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...
Pharmabiz1d
NPPA revises ceiling prices of scheduled drugs as per increase in annual WPI
NPPA revises ceiling prices of scheduled drugs as per increase in annual WPI: Our Bureau, New Delhi Saturday, March 29, 2025, ...
Pharmabiz1d
Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy
Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...
Pharmabiz2d
AiMED welcomes Centre's move onboarding members to make EPCMD functional
AiMED welcomes Centre's move onboarding members to make EPCMD functional: Our Bureau, New Delhi Friday, March 28, 2025, 16:30 ...
Pharmabiz2d
Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer
Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer: San Jose, Calif Friday, March ...
Pharmabiz2d
Endometriosis is a chronic inflammatory condition caused due to abnormal appearance of the uterine lining. Dr Shilpa Singhal
Endometriosis is a chronic inflammatory condition caused due to abnormal appearance of the uterine lining. Dr Shilpa Singhal: Our Bureau, Chennai Friday, March 28, 2025, 14:30 Hrs ...
Pharmabiz2d
Sichuan Kelun-Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours
Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...